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Abstract 
Background: Long-term outcome of the three categories of acute coronary syndrome (ACS) in 
real-life patient cohorts is not well known. The objective of this study was to survey the 10-year 
outcome of an ACS patient cohort admitted to a university hospital and to explore factors affecting 
the outcome. 
Methods: A total of 1188 consecutive patients (median age 73 years) with ST-elevation myocardial 
infarction (STEMI), non-ST-elevation myocardial infarction (NSTEMI) or unstable angina pectoris 
(UA) in 2002–2003 were included and followed up for ≥ 10 years.  
Results: Mortality for STEMI, NSTEMI and UA patients during the follow-up period was 52.5%, 
69.9% and 41.0% (p < 0.001), respectively. In multivariable Cox regression analysis, only age and 
creatinine level at admission were independently associated with patient outcome in all the three 
ACS categories when analyzed separately. 
Conclusions: All the three ACS categories proved to have high mortality rates during long-term 
follow-up in a real-life patient cohort. NSTEMI patients had worse outcome than STEMI and UA 
patients during the whole follow-up period. Our study results indicate clear differences in the 
prognostic significance of various demographic and therapeutic parameters within the three ACS 
categories. 
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INTRODUCTION 
Acute coronary syndromes (ACS) represent a spectrum of clinical events ranging 
from unstable angina pectoris (UA) to non-ST elevation (NSTEMI) and ST-elevation myocardial 
infarction (STEMI). Despite the fact that ischemic heart disease remains the leading cause of death 
globally [1], data on long-term mortality, especially beyond the first few years, is scarce.  
Elderly patients are underrepresented or even excluded in clinical trials. As many as 
50% of real-world acute myocardial infarction (MI) patients may not be represented in randomized 
clinical trials [2]. On the other hand, the general population is aging, elderly individuals comprise 
the fastest growing segment of the population worldwide, and coronary artery disease is common in 
the elderly [3, 4]. Older MI patients are less likely to receive evidence-based care than younger 
patients (5). 
Studies have shown that UA patients have better short-term outcome than patients 
with acute MI, but long-term outcome may not differ greatly [6]. According to randomized clinical 
trials, NSTEMI patients have better outcome than STEMI patients during the first few weeks after 
the acute event, but they are at higher risk for adverse outcome over the long-term [7].  
In a prospective observational study, we previously reported 10-month outcome data 
of consecutive ACS patients (n = 1188) treated in a university hospital [8]. The aim of the present 
study was to establish the 10-year outcome data of all the three clinical entities of ACS in the same 
patient cohort. We also studied the effect of baseline clinical factors and data collected during the 
initial hospital stay on patient outcome.  
 
METHODS 
Study population 
Details of the patient selection have been described elsewhere [8]. Briefly, the 
Tampere Acute COronary Study (TACOS) study cohort consisted of 1188 ACS patients admitted to 
Tampere University hospital from the city of Tampere and 11 neighboring municipalities, a region 
of 340,000 inhabitants. From January 1st 2002 to March 31st 2003 all patients admitted to the 
emergency department presenting with acute MI as verified by an elevated blood troponin I (cTnI > 
0.2 μg/L) value were recruited. In addition, from September 1st 2002 to March 31st 2003 all 
consecutive troponin-negative patients with UA were also recruited. Patients who died in or were 
discharged from the emergency department were not included. The complete study population 
consisted of 343 (29%) patients with STEMI, 655 (55%) with NSTEMI and 190 (16%) with UA. 
The study complies with the Declaration of Helsinki. The Ethics Committee of the 
Pirkanmaa Hospital District approved the study protocol (Permission R02100). All subjects gave 
their written informed consent for participation. 
 
ACS categories 
All patients had symptoms and/or clinical signs suggestive of ACS. Patients with 
STEMI had elevated troponin levels (> 0.2 μg/L) and their electrocardiogram (ECG) fulfilled the 
predefined criteria for STEMI: ST-segment elevation in ≥ 2 adjacent leads, in leads V1–V6 ≥ 1.5 
mm (≥ 2 mm in at least one lead), in leads II, III, aVF, and I and aVL ≥ 1 mm. 
Also, in NSTEMI patients, the troponin values were elevated, but the ECG did not 
fulfil the criteria for STEMI. UA patients showed no elevation in a minimum of two cTnI levels 6–
12 h apart.  
 
Follow-up 
Data was collected by a study nurse and two of the investigators (ME and KJN). The 
follow-up was set to begin at the moment of the ECG recording used for analysis, and it ended at 
death or at the end of follow-up — March 31st 2013. Mortality was gathered by linking the personal 
identity code from the TACOS study to the Causes of Death register, maintained by Statistics 
Finland, which records 100% of deaths of Finnish citizens at home and nearly 100% abroad. 
Follow-up was complete with 716 deaths and 472 patients alive at the end of the follow up. When 
comparing mortality to literature, exact 10-year mortality was used. 
 
Statistical analysis 
Categorical variables were expressed as numbers of patients or percentages and 
continuous variables as means or medians followed by quartiles (Q1–Q3). Fisher’s exact test was 
used for categorical variables and the Mann-Whitney U or Kruskal-Wallis test for numerical 
variables. A two-tailed p-value of < 0.05 was considered statistically significant. Kaplan-Meier 
curves were used to present the unadjusted survival data. Cox regression analysis was used to 
identify the baseline and in-hospital prognostic variables concerning mortality at follow-up. Cox 
univariate and multivariable regression analyses including all the variables were presented. 
Troponin I values were used only for the STEMI and NSTEMI categories due to immeasurable low 
(< 0.2 μg/L) values in UA patients. To utilize the power of the wide study population, the variables 
previous smoking and coronary angiography were not included in the final model because of lack of 
data in a significant proportion of patients. Mortality rates at pre-specified points in time were 
calculated by dividing the amount of cumulative events before the time point by the number of 
patients at risk at the beginning of the follow-up. All calculations were performed with the SPSS 
22.0 statistical package. 
 
RESULTS 
Baseline characteristics and in-hospital data of the study patients were reported 
previously [9]. The median age of patients at study inclusion was 73 years (63–80 years) and the 
male/female ratio was 58%/42%. The NSTEMI patients were older (median age 75 years) than the 
STEMI (69 years) and UA (68 years) patients. The relative proportion of female patients was higher 
in the NSTEMI than in the STEMI and UA categories (46%, 36%, and 37%, respectively; p = 
0.003). There were no significant differences in the rate of hypertension (50–55%, p = 0.297) or 
diabetes (22–29%, p = 0.065) between the three groups. The rate of diuretic usage at admission was 
highest in the NSTEMI category (42%, 19%, and 32%, respectively; p < 0.001).  
The median survival times for the STEMI and NSTEMI categories were 9.7 years and 
4.7 years. The mean survival times were 7.3 (95% confidence interval [CI] 6.8–7.7), 5.4 (95% CI 
5.0–5.7) and 7.7 (95% CI 7.2–8.3) for STEMI, NSTEMI and UA categories, respectively (p < 
0.001). The 5-year mortality rates were 32.4%, 51.3%, and 25.3% (p < 0.001), while the 10-year 
mortality rates were 52.5%, 69.9%, and 41.0% (p < 0.001) for the STEMI, NSTEMI and UA 
categories, respectively (Fig. 1). Among all deaths, 73.9%, 72.5% and 57.7% were due to 
cardiovascular causes for the STEMI, NSTEMI and UA patient categories, respectively (p = 0.019).  
Variables predicting outcome at follow-up according to Cox univariate and 
multivariable regression analyses are presented in Table 1. Age, male gender, active smoking, 
diabetes, higher creatinine level, STEMI and NSTEMI ACS categories were independent predictors 
of worse outcome, while bypass surgery and hypertension were associated with better outcome. 
Diuretic use both at hospital arrival and discharge was associated with worse outcome, while statin 
use at discharge was associated with better outcome (Table 2).  
When multivariable Cox regression analysis was performed separately for the ACS 
categories, only age and creatinine level at admission proved to be independent outcome predictors 
for all three categories (Table 3). Active smoking was an indicator of worse outcome in both 
STEMI and NSTEMI categories. Diuretic use at discharge had a strong negative impact on outcome 
both in NSTEMI and UA patients (Table 2). In NSTEMI, which was the largest patient category, 
invasive treatment and betablocker use at discharge were associated with better outcome.   
 
DISCUSSION 
The present all-comers’ study showed that: 1) all 3 patient categories of ACS have 
poor long-term outcome, 2) NSTEMI patients have the worst outcome, 3) the survival curves of 
STEMI and NSTEMI patients stay clearly separated for a follow-up period of ≥ 10 years, 4) UA 
patients have better outcome than MI patients also in the long term, and 5) factors affecting 
outcome differ between the three ACS categories.  
 
Randomized clinical trials and the real-life setting in ACS: “Two different worlds” 
In general, there is limited data on patient outcome in ACS beyond the first few years 
[9]. Especially, there is very little long-term mortality data from complete ACS cohorts, which 
include STEMI, NSTEMI and UA patients. Existing data shows wide variation in mortality 
reflecting distinct differences between randomized controlled trials with pre-specified exclusion 
criteria and “real-life” populations, which include consecutive patients independently of co-
morbidities, ethnicity, age and gender. In randomized controlled trials of invasively treated STEMI 
patients, the 5-year mortality rate in STEMI may be as low as 10% [10]. The Global Registry of 
Acute Coronary Events (GRACE) study is widely acknowledged and has had significant impact on 
risk stratification in ACS [11]. In the “long-term” GRACE study (GRACE UK-Belgian), 5-year 
mortality of STEMI and NSTEMI patients was 19% and 22%, respectively [9]. These figures are in 
strong contrast with the corresponding mortality figures of 32.4%, and 51.3% in the present study. 
The 2002 New Zealand ACS Audit Group carried out a comprehensive collection of data from all 
ACS patients admitted to a New Zealand hospital over a 14-day period in May 2002, and found 
mortality rates close to those of the present study in STEMI patients (34%), while the mortality rate 
(33%) for NSTEMI patients was between that reported in the GRACE UK-Belgian study and the 
present study [12]. Differences in patient age is probably an important explanatory factor for the 
observed variation in mortality rates; age at study inclusion was 65/72/69 years for STEMI and 
67/73/75 years for NSTEMI in GRACE, New Zealand ACS and TACOS, respectively. Also, a 
retrospective “real life” analysis of 2,763 consecutive ACS patients found much higher mortality at 
long-term (median 8.2 years) in patients > 65 years (69.7%) compared with those ≤ 65 years 
(18.6%) [13].   
When comparing longer outcome in STEMI patients, the 10-year mortality rates in the 
New Zealand ACS audit study (48%) and the present study (52.5%) are comparable. In NSTEMI 
patients, higher 10-year mortality rates were found: 51% and 69.9%, probably not entirely 
explained by the 2-year age difference at study inclusion.  
A recent meta-analysis of 8 randomized non-ST-elevation ACS (NSTE-ACS; 
NSTEMI and UA together) trials included 6,657 patients [14]. At a mean of 10.3 year follow-up, 
the risk of all-cause mortality was 28.5%. Again, this is certainly much lower than in both NSTEMI 
(69.9%) and UA (41%) in the present study. However, the mean age of the NSTE-ACS patients in 
the meta-analysis was ~76 at the end of 10.3-year follow-up, while in the present study, the median 
age at study inclusion in NSTEMI patients was 75 years (68 years for UA) [8].  
 
STEMI/NSTEMI comparison 
Clinical trial evidence is limited with regard to the efficacy and hazards of 
pharmacological and invasive management of NSTE-ACS in the elderly. According to Alexander et 
al. [15], the age gap between trials and community populations begins at age 75 and widens with 
age. Studies have shown that long-term outcome in NSTEMI patients is not improving, and this has 
been attributed to the fact that they have a more complex phenotype [16]. Compared with STEMI 
patients, those with NSTEMI tend to be older and have more comorbidity. In the Worcester Heart 
Attack Study (WHAS) with a population 3,762 patients, post-discharge death rates in a sub-cohort 
with longer follow-up, 5-year death rates for STEMI (mean age for all patients 65.5 years) and 
NSTEMI (mean age for all patients 72.6 years) were 30.2% and 52.4%, which are in the same range 
as in the present study: 32.4% for STEMI, 51.3% for NSTEMI [17].   
Regarding STEMI, the introduction of primary percutaneous coronary intervention 
(PCI) programs and improvements in coronary interventions and medical therapy have resulted in 
definite improvement in patient outcome [18, 19]. However, patients > 75 years of age are 
underrepresented in randomized clinical STEMI trials; age over 75 or 80 years was a 
typicalexclusion criteria in many trials [20]. Therefore, limited data is available for guidance on the 
best management of this growing subset of patients, although registry data seems to support the 
superiority of primary PCI over conservative treatment also in the elderly [21]. The Florence Acute 
Myocardial Infarction Registry (AMI-Florence) was a population-based prospective observational 
registry, where the baseline data were collected in 2000–2001 (2002–2003 in our study) [21]. In 
STEMI patients (n = 875), the 8-year mortality rate was 49%, comparable to 42.3% in the present 
study. In AMI-Florence, primary PCI was performed in 50% of the STEMI patients admitted within 
24 h, whereas in the current study 24% had PCI during the index hospital admission, while 57% 
received fibrinolytic therapy [8].  
 
Unstable angina pectoris 
Existing data on the long-term outcome of UA is scarce mainly due to the fact that 
researchers tend to combine NSTEMI and UA into NSTE-ACS [22]. It was previously reported that 
UA patients (median age at study inclusion 68 years) had low in-hospital mortality (2.6%), but at 10 
months, the mortality rate had increased to 12% [8]. With longer follow-up, 5- and 10-year 
mortality rates of UA patients clearly increased to 25.3% and 41%, respectively. The corresponding 
mortality rate at 10 years in the New Zealand ACS Audit trial was 32% [12]. In the GRACE UK-
Belgian study, 5-year mortality rate in UA was 18% [9]. With the introduction of the sensitive 
troponins to detect myocardial injury, it is probable that a considerable proportion of the UA 
patients in the present study would be classified as NSTEMI using today´s diagnostic methods [23]. 
 
Predictors of mortality 
When analyzing all patients together in the present study, the well-established 
cardiovascular risk factors retained their statistical significance as independent outcome predictors 
in the multivariable analyses. However, only age and renal dysfunction (higher creatinine levels), 
which are well documented risk factors, showed negative prognostic impact uniformly in all three 
ACS categories. For example, active smoking affected outcome only in STEMI and NSTEMI 
patients, while male gender was associated with inferior outcome only in UA patients. Previous 
study evidence for a gender difference in mortality in ACS patients is conflicting. In a major 
systematic review, Buchholz et al. [24] found considerable heterogeneity of study results when 
analyzing 26 studies reporting mortality at 5 to 9 years. Most studies reported clear attenuation of 
study results after covariates other than age were introduced in the analyses.  
The fact that diuretic use had the strongest impact on the outcome of patients in the 
NSTEMI category is not surprising, as these patients were older and probably had more co-
morbidity, such as heart failure. In the PRAIS-UK registry, which dealt with NSTEMI patients 
treated in the late 1990’s, history of heart failure was a predictor of inferior outcome during 10-year 
follow-up [25].  
Herein, there is no definite explanation for the protective effect on outcome of 
hypertension in the NSTEMI patients, other than possible positive effects on use of hypertensive 
medication on ventricular remodeling. Hypertension could also maintain circulation of the kidneys 
longer in the severely ill, hypovolemic patients and hence, a delayed progression of kidney failure.  
 
Limitations of the study 
This study has clear limitations; those related to data collection and patient 
classification were described previously [8]. The follow-up of UA patients was shorter than in the 
STEMI and NSTEMI groups. The categorization of those with left bundle branch block as NSTEMI 
or UA patients could increase the risk of random error. However, only nine percent of left bundle 
branch block patients were treated with fibrinolytic therapy, which supports the decision for this 
classification. 
There are two additional limitations typical for outcome studies with long follow-up in 
patients with cardiovascular diseases. The first limitation is the low rate of invasive procedures [17]. 
Especially in STEMI, the rate of invasive procedures during the index hospital stay in the present 
study was lower than what is typical for Western countries today. Yet, most (55%) patients in the 
examined cohort had NSTE-ACS, where the rate of invasive procedures did not increase as much as 
in the treatment of STEMI [26]. In addition, in the NSTEMI category, the median age at study 
inclusion was 75 years, and older patients tend to have lower rates of invasive procedures [27]. 
Also, the use of medical therapy is known to improve outcome, such as statins, were not at the level 
that is expected in patient care today. Because of these limitations, the study results do not 
necessarily reflect the outcome of ACS patients treated according to a modern standard. Another 
general limitation of studies with long-term follow-up is the fact that changes in patient medication 
and new coronary interventions are difficult or impossible to control for.   
 
Conclusions 
All three ACS categories herein proved to have high mortality rates during long-term 
follow-up in a real-life patient cohort. NSTEMI patients had worse outcomes than STEMI and UA 
patients during the whole follow-up period. The present study results also indicates considerable 
differences in the prognostic significance of various demographic and therapeutic parameters within 
the three ACS categories.  
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    Univariate   Multivariable   
 Median (IQR) 
or % 
Valid 
cases 
 Hazard 
ratio 
95% CI P  Hazard ratio 95% CI P 
Age 73 (63–80) 1188  1.075 1.067–1.084 < 0.001  1.056 1.044–1.069 < 0.001 
Male gender 58 1188  0.689 0.595–0.798 < 0.001  1.283 1.060–1.552 0.011 
Active smoking 19 1081  0.647 0.517–0.810 < 0.001  1.590 1.218–2.076 0.001 
Ex-smoker 45 849  1.013 0.849–1.208 0.885  Not in the final model¤   
Hypertension 54 1179  1.147 0.989–1.331 0.070  0.763 0.621–0.938 0.010 
Diabetes:           
   No diabetes 74 1184  1       
   Diabetes mellitus type 1 1 1184  1.925 0.995–3.722 0.052  2.811 1.284–6.154 0.010 
   Diabetes mellitus type 2 25 1184  1.744 1.487–2.045 < 0.001  1.287 1.067–1.552 0.008 
Previous MI 24 1172  1.472 1.251–1.733 < 0.001  0.950 0.768-1.176 0.639 
Plasma creatinine [/10 
µmol/L]* 
8.7 (7.2–10.9) 1186  1.050 1.040–1.060 < 0.001  1.023 1.008–1.039 0.003 
cTnI [/10 µmol/L]* 0.47 (0.06-2.6) 1188  1.000 0.099–1.010 0.979  1.005 1.000–1.011 0.060 
C-reactive protein [/10 mg/L]*# 1.2 (0.34–5.69) 1173  1.040# 1.030–1.049# < 0.001  1.006 0.994–1.019 0.306 
Systolic blood pressure 145 (125–167) 1187  0.996 0.994–0.999 0.003  0.998 0.994–1.002 0.297 
Diastolic blood pressure 80 (69–91) 1187  0.989 0.984–0.993 < 0.001  1.002 0.996–1.009 0.476 
PCIa 15 1188  0.426 0.328–0.553 < 0.001  0.680 0.453–1.020 0.063 
CABG 9 1188  0.554 0.413–0.742 < 0.001  0.532 0.383–0.738 < 0.001 
Category of ACS:  1188         
   UAP 16   1       
   STEMI 29   1.372 1.051–1.790 0.020  1.699 1.216–2.374 0.002 
   NSTEMI 55   2.264 1.780–2.880 < 0.001  1.810 1.352–2.422 < 0.001 
CAG data available:  560      Not in the final model¤   
 < 50% stenosis 12   1  1     
 1-vessel disease 29   1.014 0.623–1.649 0.956     
 2-vessel disease 24   1.121 0.682–1.844 0.652     
 3-vessel disease 27   1.899 1.194–3.021 0.007     
 Left main diseaseb 8   3.133 1.818–5.397 < 0.001     
Table 1. Prognostic factors related to mortality according to univariate and multivariable Cox regression analyses. 
 
IQR —  interquartile range; CI — confidence interval; MI — myocardial infarction; cTnI — cardiac troponin I; PCI — percutaneous coronary invention; CABG — coronary 
artery bypass surgery; ACS — acute coronary syndrome; UA — unstable angina pectoris; STEMI — ST-segment elevation myocardial infarction; NSTEMI — non-ST-
segment elevation myocardial infarction; CAG — coronary angiography 
*Values at admission, for cTNI and C-reactive protein highest of two values 6–12 h apart 
¤To utilize the power of the wide study population, ex-smoking and CAG were not included in the final model because of lack of data in a significant proportion of patients 
#For plasma creatinine, cTnI and C-reactive protein, hazard ratio and CI were calculated using values per 10 mg/L 
aPrimary PCI was not standard therapy in STEMI patients 
bEither isolated or in association with 1-, 2- or 3-vessel disease 
 
 
    Univariate   Multivariable   
 Median (IQR) 
or % 
Valid 
cases 
 Hazard 
ratio 
95% CI P  Hazard ratio 95% CI P 
Medication at admission:           
   ASA 45 1184  1.110 0.958–1.286 0.165  0.968 0.785–1.193 0.758 
   Beta-blocker 50 1186  1.283 1.108–1.487 0.001  1.078 0.874–1.329 0.485 
   Nitrate 48 1186  1.603 1.383–1.859 < 0.001  1.014 0.816–1.260 0.900 
   Calcium-antagonist 21 1186  1.228 1.032–1.461 0.021  1.141 0.903–1.442 0.270 
   Diuretic 34 1186  3.161 2.721–3.672 < 0.001  1.718 1.392–2.121 < 0.001 
   Statin 22 1187  0.747 0.621–0.900 0.002  1.279 0.982–1.665 0.068 
   ACE-inhibitor 45 1185  1.520 1.286–1.797 < 0.001  0.964 0.764–1.218 0.761 
   AT2-inhibitor 7 1186  0.963 0.720–1.287 0.798  1.306 0.824–2.071 0.256 
   Digitalis 12 1187  2.566 2.112–3.116 < 0.001  1.100 0.823–1.469 0.520 
   Warfarin 45 1187  2.053 1.682–2.505 < 0.001  1.004 0.714–1.411 0.983 
   Clopidogrel 1 1186  0.370 0.139–0.989 0.047  0.575 0.203–1.627 0.297 
Medication at discharge:           
   Aspirin 88 1188  0.490 0.401–0.599 < 0.001  0.880 0.656–1.180 0.392 
   Beta-blocker 93 1188  0.742 0.562–0.979 0.035  0.691 0.475–1.004 0.053 
   Nitrate 72 1188  1.317 1.108–1.564 0.002  1.005 0.810–1.246 0.967 
   Calcium-antagonist 18 1188  1.160 0.966–1.393 0.113  0.960 0.751–1.226 0.741 
   Diuretic 50 1188  3.273 2.751–3.893 < 0.001  1.702 1.349–2.147 <0.001 
   Statin 34 1188  0.381 0.328–0.442 < 0.001  0.710 0.573–0.880 0.002 
   ACE-inhibitor 47 1188  1.193 1.031–1.382 0.018  1.020 0.839–1.242 0.841 
   AT2-inhibitor 8 1188  0.906 0.683–1.202 0.493  0.778 0.501–1.208 0.263 
   Digitalis 16 1188  2.515 2.110–2.997 < 0.001  1.147 0.8721.509 0.327 
   Warfarin 24 1188  1.337 1.136–1.574 < 0.001  1.052 0.822–1.345 0.688 
   Clopidogrel 20 1188  0.490 0.396–0.605 < 0.001  0.927 0.661–1.300 0.662 
 
Table 2. Prognostic factors related to mortality according to univariate and multivariable Cox regression analyses 
 
IQR — interquartile range; CI — confidence interval; ASA — acetylsalicylic acid; ACE — angiotensin-converting enzyme; AT2 — angiotensin II 
Table 3. Characteristics significant in at least one of the three ACE categories retained in the final 
multivariate Cox regression model. 
 
ACE — angiotensin-converting enzyme; CABG — coronary artery bypass surgery; CI — confidence interval; cTnI — 
cardiac troponin I; MI — myocardial infarction; NSTEMI — non-ST-segment elevation myocardial infarction; PTCA 
— percutaneous transluminal coronary angioplasty; STEMI — ST-segment elevation myocardial infarction; UAP — 
unstable angina pectoris 
 
STEMI category 
Characteristic Hazard ratio 95% CI P 
Age 
Male gender 
Active smoking 
Hypertension 
Diabetes: 
      No diabetes 
      Diabetes mellitus type 1 
      Diabetes mellitus type 2 
Previous MI 
Plasma creatinine [/10 µmol/L] 
C-reactive protein [/10 mg/L] 
cTnI [/10µmol/L] 
Medication at admission 
      Diuretic 
      ACE-inhibitor 
      Warfarin  
PTCA 
CABG 
Medication at discharge: 
      Beta-blocker 
      Diuretic 
      Statin 
      Digitalis 
1.067 
1.141 
2.017 
0.832 
 
 
7.949 
1.509 
0.658 
1.092 
1.029 
1.005 
 
1.357 
0.625 
0.638 
0.813 
0.822 
 
0.841 
1.137 
0.573 
2.111 
1.044–1.091 
0.744–1.748 
1.237–3.289 
0.568–1.220 
 
 
1.609–39.264 
1.020–2.233 
0.413–1.048 
1.032–1.155 
1.004–1.055 
0.999–1.012 
 
0.881–2.089 
0.375–1.041 
0.311–1.307 
0.505–1.309 
0.416–1.623 
 
0.355–1.994 
0.768–1.682 
0.386–0.853 
1.136–3.925 
< 0.001 
0.546 
0.005 
0.346 
 
 
0.011 
0.040 
0.078 
0.002 
0.022 
0.114 
 
0.166 
0.071 
0.219 
0.394 
0.572 
 
0.695 
0.521 
0.006 
0.018 
NSTEMI category 
 Age 
Male gender 
Active smoking 
Hypertension 
Diabetes: 
    No diabetes 
    Diabetes mellitus type 1 
    Diabetes mellitus type 2 
Previous MI 
Plasma creatinine [/10 µmol/L] 
C-reactive protein [/10 mg/L] 
cTnI [/10µmol/L] 
Medication at admission: 
    Diuretic 
    ACE-inhibitor 
    Warfarin 
1.044 
1.121 
1.537 
0.753 
 
 
1.774 
1.144 
1.066 
1.037 
0.999 
1.035 
 
1.827 
1.104 
1.370 
1.029–1.060 
0.892–1.410 
1.091–2.165 
0.593–0.955 
 
 
0.637–4.939 
0.911–1.436 
0.842–1.351 
1.020–1.055 
0.985–1.013 
1.014–1.058 
 
1.411–2.366 
0.864–1.412 
1.003–1.870 
< 0.001 
0.328 
0.014 
0.019 
 
 
0.272 
0.247 
0.595 
< 0.001 
0.874 
0.001 
 
< 0.001 
0.429 
0.048 
PTCA 
CABG 
Medication at discharge: 
    Beta-blocker 
    Diuretic 
    Statin 
    Digitalis 
 
0.569 
0.456 
 
0.554 
2.104 
0.795 
1.250 
0.374–0.864 
0.310–0.673 
 
0.352–0.872 
1.547–2.862 
0.629–1.005 
0.951–1.642 
0.008 
< 0.001 
 
0.011 
< 0.001 
0.055 
0.109 
UAP category 
Age 1.117 1.073–1.164 < 0.001 
Male gender 3.400 1.625–7.113 0.001 
Active smoking 1.995 0.614–6.481 0.251 
Hypertension 1.003 0.558–1.805 0.992 
Diabetes:    
    No diabetes    
    Diabetes mellitus type 1 131.881 0.882–19712.989 0.056 
    Diabetes mellitus type 2 2.103 1.173–3.770 0.013 
Previous MI 0.696 0.361–1.345 0.281 
Plasma creatinine [/10 µmol/L] 0.946 0.905–0.989 0.015 
C-reactive protein [/10 mg/L] 1.221 1.102–1.352 < 0.001 
Medication at admission:    
    Diuretic 0.683 0.296–1.577 0.372 
    ACE-inhibitor 1.354 0.704–2.606 0.364 
    Warfarin 0.700 0.342–1.429 0.327 
PTCA 0.028 0.000–4.118 0.160 
CABG 0.222 0.047–1.039 0.056 
Medication at discharge:    
    Beta-blocker 1.281 0.571–2.874 0.548 
    Diuretic 4.807 1.937–11.931 0.001 
    Statin 1.131 0.610–2.099 0.695 
    Digitalis 0.907 0.432–1.900 0.795 
 
 Figure 1. Kaplan-Meier estimates of survival and the number at risk at different time points in the 
three acute coronary syndrome categories. The y axis shows the proportion of patients alive at 
different time points (1.0 = 100%).  
 

